Treatment outcome in patients with triple negative early stage breast cancers compared with other molecular subtypes
Radiation Oncology Journal. 2012;30(3):124 
Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies
The Breast. 2019;44:S27
Cisplatin–gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients
The Breast. 2010;19(3):246-248
Early Stage Triple Negative and HER2 Overexpression Breast Cancers Have Similar Survivals in Chinese Patients
The Breast Journal. 2012;18(3):286-288
Outcome After Breast Conservation Treatment with Radiation for Women with Triple-Negative Early-Stage Invasive Breast Carcinoma
Clinical Breast Cancer. 2009;9(2):96-100
Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer
Tumor Biology. 2019;41(5):101042831984708
Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy
PLOS ONE. 2015;10(6):e0129356
Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers
The Lancet Oncology. 2019;20(7):e390-e396
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
Breast Cancer Research. 2010;12(5):
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Cancers. 2020;12(4):819